Skip to main content
. 2021 Jan 19;35(4):938–947. doi: 10.1111/jdv.17002

Figure 1.

Figure 1

Study design. A, assigned; EOF, end of follow‐up; EOM, end of maintenance period; EOT, end of treatment; HD, high dose; LD, low dose; PASI, Psoriasis Area and Severity Index; R, randomized; SEC, secukinumab; WK, week.